December 20, 2011
8:11-cv-03680
Derivative Litigation
28:1332 Diversity - Stockholders Suits
News Coverage, Answers, Appeals, Complaints, Motions, Orders, Trial Notes
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.
A Human Genome Sciences Inc. shareholder lodged a derivative complaint Wednesday against the biotech company's CEO and several other officers and directors, alleging they hid from investors the fact that lupus drug Benlysta caused an elevated rate of suicide among users.